Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 239

1.

Immunohistochemical expression and prognostic value of ER, PR and HER2/neu in pancreatic and small intestinal neuroendocrine tumors.

Arnason T, Sapp HL, Barnes PJ, Drewniak M, Abdolell M, Rayson D.

Neuroendocrinology. 2011;93(4):249-58. doi: 10.1159/000326820. Epub 2011 Apr 10.

PMID:
21487213
2.
3.

Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.

Arapantoni-Dadioti P, Valavanis C, Gavressea T, Tzaida O, Trihia H, Lekka I.

J BUON. 2012 Apr-Jun;17(2):277-83.

PMID:
22740206
4.
5.

Receptor conversion in distant breast cancer metastases.

Hoefnagel LD, van de Vijver MJ, van Slooten HJ, Wesseling P, Wesseling J, Westenend PJ, Bart J, Seldenrijk CA, Nagtegaal ID, Oudejans J, van der Valk P, van der Groep P, de Vries EG, van der Wall E, van Diest PJ.

Breast Cancer Res. 2010;12(5):R75. doi: 10.1186/bcr2645. Epub 2010 Sep 23.

6.

Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases.

Wang-Rodriguez J, Cross K, Gallagher S, Djahanban M, Armstrong JM, Wiedner N, Shapiro DH.

Mod Pathol. 2002 Aug;15(8):853-61.

7.

Coordinated expression of ER, PR and HER2 define different prognostic subtypes among poorly differentiated breast carcinomas.

Fernandes RC, Bevilacqua JL, Soares IC, Siqueira SA, Pires L, Hegg R, Carvalho FM.

Histopathology. 2009 Sep;55(3):346-52. doi: 10.1111/j.1365-2559.2009.03380.x.

PMID:
19723150
8.

Morphological profile and association of HER-2/neu with prognostic markers in breast carcinoma in Northern Pakistan.

Sharif MA, Mamoon N, Mushtaq S, Khadim MT.

J Coll Physicians Surg Pak. 2009 Feb;19(2):99-103. doi: 02.2009/JCPSP.99103.

PMID:
19208313
9.

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.

11.
12.

Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan.

Sughayer MA, Al-Khawaja MM, Massarweh S, Al-Masri M.

Pathol Oncol Res. 2006;12(2):83-6. Epub 2006 Jun 24.

13.

Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer.

Chen XS, Ma CD, Wu JY, Yang WT, Lu HF, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.

Tumori. 2010 Jan-Feb;96(1):103-10.

14.

Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.

Lindström LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, Hatschek T, Skoog L, Bergh J.

J Clin Oncol. 2012 Jul 20;30(21):2601-8. doi: 10.1200/JCO.2011.37.2482. Epub 2012 Jun 18.

15.

Obesity and risk of the less commonly diagnosed subtypes of breast cancer.

Stark A, Schultz D, Kapke A, Nadkarni P, Burke M, Linden M, Raju U.

Eur J Surg Oncol. 2009 Sep;35(9):928-35. doi: 10.1016/j.ejso.2008.11.009. Epub 2009 Jan 1.

PMID:
19121564
16.

Do we need HER-2/neu testing for all patients with primary breast carcinoma?

Taucher S, Rudas M, Mader RM, Gnant M, Dubsky P, Bachleitner T, Roka S, Fitzal F, Kandioler D, Sporn E, Friedl J, Mittlböck M, Jakesz R.

Cancer. 2003 Dec 15;98(12):2547-53.

17.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
18.

Her-2/neu status: a neglected marker of prognostication and management of breast cancer patients in India.

Zubeda S, Kaipa PR, Shaik NA, Mohiuddin MK, Vaidya S, Pavani B, Srinivasulu M, Latha MM, Hasan Q.

Asian Pac J Cancer Prev. 2013;14(4):2231-5.

19.

MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer.

Lowery AJ, Miller N, Devaney A, McNeill RE, Davoren PA, Lemetre C, Benes V, Schmidt S, Blake J, Ball G, Kerin MJ.

Breast Cancer Res. 2009;11(3):R27. doi: 10.1186/bcr2257. Epub 2009 May 11.

20.

Immunohistochemical characterization of molecular subtypes of invasive breast cancer: a study from North India.

Verma S, Bal A, Joshi K, Arora S, Singh G.

APMIS. 2012 Dec;120(12):1008-19. doi: 10.1111/j.1600-0463.2012.02933.x. Epub 2012 Jul 26.

PMID:
23030684
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk